Business Context and Reporting Period
Company: Harvard Bioscience, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2010
Business Overview: A global developer, manufacturer, and marketer of specialized apparatus and scientific instruments for life science research and regenerative medicine. The company operates primarily through two divisions: Life Science Research Tools (LSRT) and Regenerative Medical Devices (RMD). It sells products via catalogs, a direct sales force, and distributors (including GE Healthcare) to researchers in over 100 countries.
Key Financial Metrics
| Metric | 2010 | 2009 | Change |
|---|---|---|---|
| Revenues | $108.2 million | $85.8 million | +26.1% |
| Gross Profit | $51.8 million | $41.7 million | +24.2% |
| Gross Margin | 47.9% | 48.6% | -0.7 pts |
| Operating Income | $10.2 million | $8.1 million | +26.8% |
| Net Income | $19.0 million | $7.2 million | +163.8% |
| Diluted EPS | $0.65 | $0.24 | +170.8% |
| Cash and Equivalents | $19.7 million | $16.6 million | +18.7% |
| Working Capital | $47.3 million | $35.9 million | +31.7% |
| Long-Term Debt | $18.0 million | $13.3 million | +35.3% |
Note: Net income for 2010 includes a significant non-cash tax benefit of $11.3 million from the reversal of valuation allowances on deferred tax assets.
Material Changes vs. Prior Period
- Revenue Growth: Driven primarily by acquisitions (Denville Scientific and Coulbourn Instruments contributed $18.5 million) and 6.1% organic growth. A stronger U.S. dollar negatively impacted revenue by $1.3 million.
- Profitability Surge: Net income more than doubled, largely due to a $9.5 million income tax benefit (reversal of valuation allowances) compared to a $2.7 million tax expense in 2009. Operating income grew organically due to new product launches and operational improvements.
- Debt Increase: Borrowings under the $20.0 million credit facility increased to $18.0 million to fund acquisitions and stock repurchases.
- Restructuring: The company incurred $0.5 million in restructuring charges in 2010 related to workforce reductions in Spain and the U.K.
Guidance, Outlook, and Risks
Management Commentary & Strategy:
- Acquisitions: The company continues a "tuckunder" acquisition strategy to expand product lines in niche markets.
- Regenerative Medicine: Investing in long-term growth opportunities, including the "InBreath" bioreactor and stem cell therapy injectors. A clinical syringe pump is expected to be submitted to the FDA in 2011.
- Product Launches: New products like the Pump 11 Elite and KDS 100 Legato are expected to drive organic growth in 2011.
Risks and Contingencies:
- Customer Concentration: GE Healthcare accounted for 10% of 2010 revenues. The company notes that sales to GE may be lower in 2011 due to high inventory levels of a specific product.
- Foreign Currency: Approximately 38% of business is conducted in foreign currencies (primarily British Pound and Euro). A stronger U.S. dollar negatively impacts reported earnings.
- Goodwill Impairment: Goodwill and intangible assets represent 45% of total assets. Impairment charges could occur if stock price or cash flows decline.
- Capital Requirements: The company may need to raise additional capital for future acquisitions, which could dilute existing shareholders.
Investor Verification Checklist
- Tax Benefit Sustainability: Verify the sustainability of the $11.3 million tax benefit derived from the reversal of valuation allowances, as this significantly inflated 2010 net income.
- GE Healthcare Sales: Monitor Q1 2011 sales to GE Healthcare to confirm if the anticipated drop in microliter spectrophotometer sales materializes.
- Debt Covenants: Review compliance with the $20.0 million credit facility covenants, particularly given the high utilization ($18.0 million outstanding).
- Regenerative Medicine Progress: Track the regulatory approval timeline for the clinical syringe pump and commercial adoption of bioreactor products.
- Organic Growth Rate: Assess whether the 6.1% organic growth rate is sustainable without further acquisitions.